Anne-Paule Gimenez-Roqueplo

List of Publications by Year in Descending Order

174 papers	15,607 citations	60 h-index	123 g-index
192 ext. papers	18,369 ext. citations	6.2 avg, IF	6.04 L-index

#	Paper	IF	Citations
174	Expression of LHCGR (Luteinizing Hormone/Chorionic Gonadotrophin Receptor) in Pheochromocytomas Unveils an Endocrine Mechanism Connecting Pregnancy and Epinephrine Overproduction.. *Hypertension*, **2022**, HYPERTENSIONAHA12118864	8.5	1
173	Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 1111-1128	5.6	6
172	Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First Appraisal. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 2726-2737	5.6	1
171	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. *Nature Reviews Endocrinology*, **2021**, 17, 435-444	15.2	12
170	Loss of SDHB Promotes Dysregulated Iron Homeostasis, Oxidative Stress, and Sensitivity to Ascorbate. *Cancer Research*, **2021**, 81, 3480-3494	10.1	4
169	MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features. *Modern Pathology*, **2021**, 34, 647-659	9.8	5
168	Genotype-Phenotype Features of Germline Variants of the TMEM127 Pheochromocytoma Susceptibility Gene: A 10-Year Update. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e350-e364	5.6	2
167	Germline DLST Variants Promote Epigenetic Modifications in Pheochromocytoma-Paraganglioma. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 459-471	5.6	1
166	Screening of a Large Cohort of Asymptomatic SDHx Mutation Carriers in Routine Practice. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e1301-e1315	5.6	1
165	International initiative for a curated variant database improving the diagnosis of hereditary paraganglioma and pheochromocytoma. *Journal of Medical Genetics*, **2021**,	5.8	1
164	Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1. *Modern Pathology*, **2021**,	9.8	3
163	Functional Characterization of TMEM127 Variants Reveals Novel Insights into Its Membrane Topology and Trafficking. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	2
162	An overview of 20´years of genetic studies in pheochromocytoma and paraganglioma. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2020**, 34, 101416	6.5	34
161	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	11
160	Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. *Journal of Hypertension*, **2020**, 38, 1443-1456	1.9	62
159	Germline mutations in the new E1' cryptic exon of the gene in patients with tumours of von Hippel-Lindau disease spectrum or with paraganglioma. *Journal of Medical Genetics*, **2020**, 57, 752-759	5.8	7
158	Pheochromocytoma and Paraganglioma in Children and Adolescents: Experience of the French Society of Pediatric Oncology (SFCE). *Journal of the Endocrine Society*, **2020**, 4, bvaa039	0.4	7

157	Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study. *Endocrine Connections*, **2020**, 9, 489-497	3.5	8
156	HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop. *Endocrine-Related Cancer*, **2020**, 27, T41-T52	5.7	17
155	Overexpression of miR-483-5p is confined to metastases and linked to high circulating levels in patients with metastatic pheochromocytoma/paraganglioma. *Clinical and Translational Medicine*, **2020**, 10, e260	5.7	2
154	Transcriptome Analysis of lncRNAs in Pheochromocytomas and Paragangliomas. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	10
153	Succinate detection using in vivo H-MR spectroscopy identifies germline and somatic SDHx mutations in paragangliomas. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 1510-1517	8.8	10
152	Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	7
151	Usefulness of FDG-PET/CT-Based Radiomics for the Characterization and Genetic Orientation of Pheochromocytomas Before Surgery. *Cancers*, **2020**, 12,	6.6	3
150	Carbonic anhydrase 9 immunohistochemistry as a tool to predict or validate germline and somatic VHL mutations in pheochromocytoma and paraganglioma-a retrospective and prospective study. *Modern Pathology*, **2020**, 33, 57-64	9.8	18
149	TET-Mediated Hypermethylation Primes SDH-Deficient Cells for HIF2□Driven Mesenchymal Transition. *Cell Reports*, **2020**, 30, 4551-4566.e7	10.6	22
148	Emerging molecular markers of metastatic pheochromocytomas and paragangliomas. *Annales D□Endocrinologie*, **2019**, 80, 159-162	1.7	12
147	Successful Targeting of an ATG7-RAF1 Gene Fusion in Anaplastic Pleomorphic Xanthoastrocytoma With Leptomeningeal Dissemination.. *JCO Precision Oncology*, **2019**, 3, 1-7	3.6	2
146	Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma. *Journal of Medical Genetics*, **2019**, 56, 513-520	5.8	38
145	Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and/or Pheochromocytoma. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 1109-1118	5.6	54
144	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 2367-2374	5.6	57
143	Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. *Theranostics*, **2019**, 9, 4946-4958	12.1	30
142	Evolutionarily conserved susceptibility of the mitochondrial respiratory chain to SDHI pesticides and its consequence on the impact of SDHIs on human cultured cells. *PLoS ONE*, **2019**, 14, e0224132	3.7	15
141	Parler □l□enfant du risque de maladie g□□ique. *Corps Et Psychisme*, **2019**, N°75, 79	0.1	
140	Adrenal tumors: when to search for a germline abnormality?. *Current Opinion in Oncology*, **2019**, 31, 230-235	4.5	3

139	Pheochromocytoma/Paraganglioma: Management, Genetics, and Follow-up **2019**, 469-477		
138	Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma. *Clinical Cancer Research*, **2019**, 25, 760-770	12.9	54
137	Germline Mutations in the Mitochondrial 2-Oxoglutarate/Malate Carrier Gene Confer a Predisposition to Metastatic Paragangliomas. *Cancer Research*, **2018**, 78, 1914-1922	10.1	71
136	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. *Genetics in Medicine*, **2018**, 20, 1652-1662	8.1	33
135	Vemurafenib and cobimetinib overcome resistance to vemurafenib in -mutant ganglioglioma. *Neurology*, **2018**, 91, 523-525	6.5	14
134	Pheochromocytoma: When to search a germline defect?. *Presse Medicale*, **2018**, 47, e109-e118	2.2	6
133	Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations. *European Journal of Human Genetics*, **2018**, 26, 1732-1742	5.3	23
132	Identification of a new exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease. *Blood*, **2018**, 132, 469-483	2.2	37
131	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. *Cancer Cell*, **2017**, 31, 181-193	24.3	350
130	68Ga-DOTATATE PET/CT Versus MRI: Why the Comparison of 68Ga-DOTATATE PET/CT to an Appropriate MRI Protocol Is Essential. *Journal of Nuclear Medicine*, **2017**, 58, 184-185	8.9	
129	Successful response to pegylated interferon alpha in a patient with recurrent paraganglioma. *Endocrine-Related Cancer*, **2017**, 24, L7-L11	5.7	2
128	Risk assessment of maternally inherited SDHD paraganglioma and phaeochromocytoma. *Journal of Medical Genetics*, **2017**, 54, 125-133	5.8	25
127	Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers. *Clinical Genetics*, **2017**, 92, 606-615	4	63
126	The mTORC1 Complex Is Significantly Overactivated in SDHX-Mutated Paragangliomas. *Neuroendocrinology*, **2017**, 105, 384-393	5.6	6
125	Nationwide French Study of RET Variants Detected from 2003 to 2013 Suggests a Possible Influence of Polymorphisms as Modifiers. *Thyroid*, **2017**, 27, 1511-1522	6.2	28
124	Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. *Nature Reviews Endocrinology*, **2017**, 13, 233-247	15.2	140
123	Risk Profile of the RET A883F Germline Mutation: An International Collaborative Study. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 2069-2074	5.6	27
122	Mitochondrial Deficiencies in the Predisposition to Paraganglioma. *Metabolites*, **2017**, 7,	5.6	14

121	In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma. *Clinical Cancer Research*, **2016**, 22, 1120-9	12.9	43
120	From Nf1 to Sdhb knockout: Successes and failures in the quest for animal models of pheochromocytoma. *Molecular and Cellular Endocrinology*, **2016**, 421, 40-8	4.4	24
119	A SDHC Founder Mutation Causes Paragangliomas (PGLs) in the French Canadians: New Insights on the SDHC-Related PGL. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 4710-4718	5.6	20
118	Rethinking pheochromocytomas and paragangliomas from a genomic perspective. *Oncogene*, **2016**, 35, 1080-9	9.2	41
117	The value of a rapid contrast-enhanced angio-MRI protocol in the detection of head and neck paragangliomas in SDHx mutations carriers: a retrospective study on behalf of the PGL.EVA investigators. *European Radiology*, **2016**, 26, 1696-704	8	19
116	PHACTR1 Is a Genetic Susceptibility Locus for Fibromuscular Dysplasia Supporting Its Complex Genetic Pattern of Inheritance. *PLoS Genetics*, **2016**, 12, e1006367	6	99
115	Pheochromocytoma and paraganglioma: molecular testing and personalized medicine. *Current Opinion in Oncology*, **2016**, 28, 5-10	4.2	34
114	The MITF, p.E318K Variant, as a Risk Factor for Pheochromocytoma and Paraganglioma. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 4764-4768	5.6	12
113	European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. *European Journal of Endocrinology*, **2016**, 174, G1-G10	6.5	230
112	A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. *Lancet, The*, **2016**, 388, 2665-2712	40	413
111	Functional and in silico assessment of MAX variants of unknown significance. *Journal of Molecular Medicine*, **2015**, 93, 1247-55	5.5	17
110	A germline mutation in PBRM1 predisposes to renal cell carcinoma. *Journal of Medical Genetics*, **2015**, 52, 426-30	5.8	24
109	Screening in asymptomatic SDHx mutation carriers: added value of □H-FDG PET/CT at initial diagnosis and 1-year follow-up. *European Journal of Nuclear Medicine and Molecular Imaging*, **2015**, 42, 868-76	8.8	17
108	DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. *Clinical Cancer Research*, **2015**, 21, 3020-30	12.9	44
107	Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism. *Nature Communications*, **2015**, 6, 8784	17.4	128
106	Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. *Nature Communications*, **2015**, 6, 6044	17.4	120
105	Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. *Nature Reviews Endocrinology*, **2015**, 11, 101-11	15.2	311
104	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). *Modern Pathology*, **2015**, 28, 807-21	9.8	142

103	Immunohistochemical expression of stem cell markers in pheochromocytomas/paragangliomas is associated with SDHx mutations. *European Journal of Endocrinology*, **2015**, 173, 43-52	6.5	14
102	SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, E287-91	5.6	39
101	Vascular pattern analysis for the prediction of clinical behaviour in pheochromocytomas and paragangliomas. *PLoS ONE*, **2015**, 10, e0121361	3.7	10
100	Oncogenic features of the bone morphogenic protein 7 (BMP7) in pheochromocytoma. *Oncotarget*, **2015**, 6, 39111-26	3.3	11
99	Deciphering the molecular basis of invasiveness in Sdhb-deficient cells. *Oncotarget*, **2015**, 6, 32955-65	3.3	44
98	Unsuspected task for an old team: succinate, fumarate and other Krebs cycle acids in metabolic remodeling. *Biochimica Et Biophysica Acta - Bioenergetics*, **2014**, 1837, 1330-7	4.6	53
97	Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E369-73	5.6	71
96	p.Ala541Thr variant of MEN1 gene: a non deleterious polymorphism or a pathogenic mutation?. *Annales D'Endocrinologie*, **2014**, 75, 133-40	1.7	10
95	Oncometabolites-driven tumorigenesis: From genetics to targeted therapy. *International Journal of Cancer*, **2014**, 135, 2237-48	7.5	99
94	Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. *Human Molecular Genetics*, **2014**, 23, 2440-6	5.6	261
93	Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 1915-42	5.6	1415
92	Malignant head/neck paragangliomas. Comparative study. *European Annals of Otorhinolaryngology, Head and Neck Diseases*, **2014**, 131, 159-66	2.2	32
91	Peritoneal implantation of pheochromocytoma following tumor capsule rupture during surgery. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E2681-5	5.6	29
90	Vascular endothelial growth factor-A is associated with chronic mountain sickness in the Andean population. *High Altitude Medicine and Biology*, **2014**, 15, 146-54	1.9	11
89	SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. *International Journal of Cancer*, **2014**, 135, 2711-20	7.5	110
88	Genetic basis of congenital erythrocytosis: mutation update and online databases. *Human Mutation* , **2014**, 35, 15-26	4.7	82
87	Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis. *Cancer Research*, **2014**, 74, 6554-64	10.1	18
86	Mutations de gènes impliqués dans le métabolisme énergétique et cancer. *Oncologie*, **2013**, 15, 441-447	1	

85	SDH mutations establish a hypermethylator phenotype in paraganglioma. *Cancer Cell*, **2013**, 23, 739-52	24.3	492
84	One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 4006-12	5.6	75
83	Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E162-73	5.6	106
82	TMEM127 screening in a large cohort of patients with pheochromocytoma and/or paraganglioma. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, E805-9	5.6	49
81	The genetics of paragangliomas. *European Annals of Otorhinolaryngology, Head and Neck Diseases*, **2012**, 129, 315-8	2.2	30
80	An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. *Hormone and Metabolic Research*, **2012**, 44, 328-33	3.1	220
79	Identity by descent mapping of founder mutations in cancer using high-resolution tumor SNP data. *PLoS ONE*, **2012**, 7, e35897	3.7	8
78	Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma. *Endocrine Pathology*, **2012**, 23, 34-42	4.2	60
77	Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, E954-62	5.6	69
76	Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. *Human Molecular Genetics*, **2012**, 21, 5397-405	5.6	111
75	HIF2A mutations in paraganglioma with polycythemia. *New England Journal of Medicine*, **2012**, 367, 2161; author reply 2161-2	59.2	50
74	Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. *Hormone and Metabolic Research*, **2012**, 44, 385-9	3.1	48
73	A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma. *Hormone and Metabolic Research*, **2012**, 44, 359-66	3.1	80
72	Presymptomatic genetic testing in minors at risk of paraganglioma and pheochromocytoma: our experience of oncogenetic multidisciplinary consultation. *Hormone and Metabolic Research*, **2012**, 44, 354-8	3.1	9
71	MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. *Clinical Cancer Research*, **2012**, 18, 2828-37	12.9	226
70	Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. *Haematologica*, **2012**, 97, 9-14	6.6	40
69	Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. *Human Molecular Genetics*, **2011**, 20, 3974-85	5.6	221
68	SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, E1472-6	5.6	220

67	A novel TMEM127 mutation in a patient with familial bilateral pheochromocytoma. *European Journal of Endocrinology*, **2011**, 164, 141-5	6.5	38
66	Spectrum of mutations in Gitelman syndrome. *Journal of the American Society of Nephrology: JASN*, **2011**, 22, 693-703	12.7	147
65	Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. *Journal of Clinical Oncology*, **2011**, 29, 4137-42	2.2	136
64	Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers. *Clinical Cancer Research*, **2010**, 16, 5133-41	12.9	87
63	Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, E373-83	5.6	259
62	SDHA is a tumor suppressor gene causing paraganglioma. *Human Molecular Genetics*, **2010**, 19, 3011-20	5.6	523
61	Evaluation of a standardized protocol for processing adrenal tumor samples: preparation for a European adrenal tumor bank. *Hormone and Metabolic Research*, **2010**, 42, 93-101	3.1	16
60	Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 1274-8	5.6	100
59	Pheochromocytomas: the (pseudo)-hypoxia hypothesis. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2010**, 24, 957-68	6.5	74
58	Rapid determination of tricarboxylic acid cycle enzyme activities in biological samples. *BMC Biochemistry*, **2010**, 11, 5	4.8	21
57	The Warburg effect is genetically determined in inherited pheochromocytomas. *PLoS ONE*, **2009**, 4, e7094	5.7	179
56	Genetics of chromaffin tumors. *Expert Review of Endocrinology and Metabolism*, **2009**, 4, 143-151	4.1	
55	The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 2817-27	5.6	304
54	Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 1938-44	5.6	96
53	Genetics of pheochromocytoma and paraganglioma in Spanish patients. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 1701-5	5.6	96
52	Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. *Endocrine-Related Cancer*, **2009**, 16, 391-400	5.7	101
51	A role for succinate dehydrogenase genes in low chemoresponsiveness to hypoxia?. *Clinical Autonomic Research*, **2009**, 19, 335-42	4.3	9
50	Penetrance and clinical consequences of a gross SDHB deletion in a large family. *Clinical Genetics*, **2009**, 75, 354-63	4	47

49	An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. *Lancet Oncology, The*, **2009**, 10, 764-71	21.7	405
48	Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. *European Journal of Human Genetics*, **2008**, 16, 79-88	5.3	377
47	Recent advances in the genetics of phaeochromocytoma and functional paraganglioma. *Clinical and Experimental Pharmacology and Physiology*, **2008**, 35, 376-9	3	53
46	Mutations associated with succinate dehydrogenase D-related malignant paragangliomas. *Clinical Endocrinology*, **2008**, 68, 561-6	3.4	39
45	Apports de COMETE à la génétique du phéochromocytome. *Bulletin De L'Academie Nationale De Medecine*, **2008**, 192, 105-116	0.1	
44	Le réseau national COMETE sur les tumeurs de la surrénale. *Bulletin De L'Academie Nationale De Medecine*, **2008**, 192, 73-85	0.1	
43	Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 1891-6	5.6	243
42	Fibromuscular dysplasia. *Orphanet Journal of Rare Diseases*, **2007**, 2, 28	4.2	197
41	Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. *Nature Clinical Practice Endocrinology and Metabolism*, **2007**, 3, 92-102		467
40	Inheritance of arterial lesions in renal fibromuscular dysplasia. *Journal of Human Hypertension*, **2007**, 21, 393-400	2.6	78
39	Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 3822-8	5.6	332
38	Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 4865-72	5.6	54
37	Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. *European Journal of Endocrinology*, **2007**, 157, 1-8	6.5	110
36	The genetic basis of pheochromocytoma: who to screen and how?. *Nature Clinical Practice Endocrinology and Metabolism*, **2006**, 2, 60-1		19
35	Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 827-36	5.6	465
34	Tricarboxylic acid cycle dysfunction as a cause of human diseases and tumor formation. *American Journal of Physiology - Cell Physiology*, **2006**, 291, C1114-20	5.4	79
33	Pheochromocytomas and secreting paragangliomas. *Orphanet Journal of Rare Diseases*, **2006**, 1, 49	4.2	53
32	Initial work-up and long-term follow-up in patients with phaeochromocytomas and paragangliomas. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2006**, 20, 421-34	6.5	30

31	Alpha1-antitrypsin gene polymorphisms are not associated with renal arterial fibromuscular dysplasia. *Journal of Hypertension*, **2006**, 24, 705-10	1.9	24
30	Phaeochromocytoma, new genes and screening strategies. *Clinical Endocrinology*, **2006**, 65, 699-705	3.4	109
29	Genetic testing in pheochromocytoma: increasing importance for clinical decision making. *Annals of the New York Academy of Sciences*, **2006**, 1073, 94-103	6.5	25
28	New advances in the genetics of pheochromocytoma and paraganglioma syndromes. *Annals of the New York Academy of Sciences*, **2006**, 1073, 112-21	6.5	17
27	Changes in urinary total metanephrine excretion in recurrent and malignant pheochromocytomas and secreting paragangliomas. *Annals of the New York Academy of Sciences*, **2006**, 1073, 383-91	6.5	18
26	Development of novel tools for the diagnosis and prognosis of pheochromocytoma using peptide marker immunoassay and gene expression profiling approaches. *Annals of the New York Academy of Sciences*, **2006**, 1073, 533-40	6.5	19
25	Mitochondrial succinate is instrumental for HIF1alpha nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. *Human Molecular Genetics*, **2005**, 14, 3263-9	5.6	131
24	Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 2110-6	5.6	254
23	Genetic testing in pheochromocytoma or functional paraganglioma. *Journal of Clinical Oncology*, **2005**, 23, 8812-8	2.2	529
22	Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency. *Hormone Research in Paediatrics*, **2005**, 63, 171-9	3.3	43
21	A thyroid nodule revealing a paraganglioma in a patient with a new germline mutation in the succinate dehydrogenase B gene. *European Journal of Endocrinology*, **2004**, 151, 433-8	6.5	35
20	Juvenile hemochromatosis HJV-related revealed by cardiogenic shock. *Blood Cells, Molecules, and Diseases*, **2004**, 33, 120-4	2.1	23
19	Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. *Blood*, **2004**, 103, 4317-21	9.2	150
18	FEATURES AT PRESENTATION AND RISK OF RECURRENCE IN PATIENTS WITH PHEOCHROMOCYTOMA. *Journal of Hypertension*, **2004**, 22, S186	1.9	
17	THE HIF-PATHWAY, NEW CANDIDATE GENES FOR PARAGANGLIOMA AND/OR PHEOCHROMOCYTOMA?. *Journal of Hypertension*, **2004**, 22, S77	1.9	
16	THE SDHB AND VHL GENES SHOULD BE SYSTEMATICALLY TESTED IN PATIENTS WITH NONSYNDROMIC PHEOCHROMOCYTOMA. *Journal of Hypertension*, **2004**, 22, S210-S211	1.9	1
15	Evidence for carotid and radial artery wall subclinical lesions in renal fibromuscular dysplasia. *Journal of Hypertension*, **2003**, 21, 2287-95	1.9	38
14	Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. *Cancer Research*, **2003**, 63, 5615-21	10.1	356

13	Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 4771-4	5.6	185
12	Génétique et hypertension artérielle : trois approches pour décrypter une maladie complexe. *Bulletin De L'Academie Nationale De Medecine*, **2002**, 186, 1595-1609	0.1	1
11	The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. *American Journal of Human Genetics*, **2001**, 69, 1186-97	11	308
10	Stent treatment for pseudocoarctation and refractory hypertension in an elderly patient with Takayasu's arteritis. *Nephrology Dialysis Transplantation*, **2000**, 15, 536-8	4.3	4
9	Characterization of a human angiotensinogen cleaved in its reactive center loop by a proteolytic activity from Chinese hamster ovary cells. *Journal of Biological Chemistry*, **2000**, 275, 10648-54	5.4	18
8	Relative expression of the RET9 and RET51 isoforms in human pheochromocytomas. *Oncology*, **2000**, 58, 311-8	3.6	26
7	Seven lessons from two candidate genes in human essential hypertension: angiotensinogen and epithelial sodium channel. *Hypertension*, **1999**, 33, 1324-31	8.5	111
6	Angiotensinogen variants and human hypertension. *Current Hypertension Reports*, **1999**, 1, 31-41	4.7	44
5	Role of N-glycosylation in human angiotensinogen. *Journal of Biological Chemistry*, **1998**, 273, 21232-8	5.4	30
4	Role of cysteine residues in human angiotensinogen. Cys232 is required for angiotensinogen-pro major basic protein complex formation. *Journal of Biological Chemistry*, **1998**, 273, 34480-7	5.4	19
3	Haplotypes of angiotensinogen in essential hypertension. *American Journal of Human Genetics*, **1997**, 60, 1448-60	11	240
2	The natural mutation Y248C of human angiotensinogen leads to abnormal glycosylation and altered immunological recognition of the protein. *Journal of Biological Chemistry*, **1996**, 271, 9838-44	5.4	14
1	A new threat identified in the use of SDHIs pesticides targeting the mitochondrial succinate dehydrogenase enzyme		3